Format

Send to

Choose Destination
J Hepatol. 2017 Sep 19. pii: S0168-8278(17)32286-9. doi: 10.1016/j.jhep.2017.09.006. [Epub ahead of print]

Effectiveness of ravidasvir plus sofosbuvir in interferon-naïve and treated patients with chronic hepatitis C genotype-4.

Author information

1
Endemic Medicine Department, Faculty of Medicine, Cairo University, Egypt.
2
Endemic Medicine Department, Faculty of Medicine, Cairo University, Egypt. Electronic address: tamerbaz@yahoo.com.
3
Endemic Medicine Department, Faculty of Medicine, Cairo University, Egypt; Cairo Fatemic Hospital, Ministry of Health, Egypt.
4
National Liver Institute, Menoufiya University, Shebeen EL Kom, Egypt.
5
Department of Microbiology, Faculty of Medicine, Minia University, El Minia, Egypt.
6
Pathology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
7
Pharco Pharmaceuticals, Amriya, Alexandria, Egypt.
8
Presidio Pharmaceuticals, Inc., San Francisco, California, USA.
9
National Liver Institute, Menoufiya University, Shebeen EL Kom, Egypt. Electronic address: iwaked@liver-eg.org.

Abstract

BACKGROUND & AIMS:

Although treatment of hepatitis C virus (HCV) and HCV-genotype-4 (GT4) has become very effective, it remains very expensive, and affordable options are needed, especially in limited resource countries. The aim of this study was to assess the efficacy and safety of the combination of ravidasvir (an NS5A inhibitor) and sofosbuvir to treat patients with chronic HCV-GT4 infection.

METHODS:

A total of 300 patients with HCV-GT4 infection were recruited in three groups: treatment-naïve patients with or without compensated Child-A cirrhosis (Group 1); interferon-experienced patients without cirrhosis (Group 2); and interferon-experienced patients with cirrhosis (Group 3). Groups 1 and 2 received ravidasvir 200 mg QD plus sofosbuvir 400 mg QD for 12 weeks and were randomized 1:1 to treatment with or without weight-based ribavirin. Group 3 patients received ravidasvir plus sofosbuvir with ribavirin and were randomized 1:1 to a treatment duration of 12 weeks or 16 weeks. The primary endpoint was sustained virologic response at 12 weeks post-treatment (SVR12).

RESULTS:

A total of 298 patients were enrolled: 149 in Group 1, 79 in Group 2 and 70 in Group 3. SVR12 was achieved in 95.3% of all patients who started the study, including 98% of patients without cirrhosis and 91% of patients with cirrhosis, whether treatment-naïve or interferon-experienced. Ribavirin intake and history of previous interferon therapy did not affect SVR12 rates. No virologic breakthroughs were observed and the study treatment was well tolerated.

CONCLUSIONS:

Treatment with ravidasvir plus sofosbuvir, with or without ribavirin, was well tolerated and associated with high sustained virologic response rate for HCV-GT4 infected patients with and without cirrhosis, regardless of previous interferon-based treatments.

TRIAL REGISTRATION NUMBER:

ClinicalTrials.gov Identifier: NCT02371408.

LAY SUMMARY:

This study evaluated efficacy and safety of the new oral hepatitis C drug ravidasvir in combination with the approved oral drug sofosbuvir in 298 patients infected with hepatitis C type 4. Our results showed that treatment with ravidasvir plus sofosbuvir, with or without ribavirin, was well tolerated and associated with high response rate in patients with and without cirrhosis.

KEYWORDS:

Genotype-4; HCV; PPI-668; Ravidasvir; Sofosbuvir; Sustained virologic response (SVR)

PMID:
28935432
DOI:
10.1016/j.jhep.2017.09.006

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center